IMPACT TO DATE
Approved indications in certain types of breast and blood cancers with high unmet need
Ongoing Phase 3 trials across 8 tumor types and stages of disease
Collaborations providing access to industry-leading innovations in oncology
Cancer steals possibility. We're taking it back.™
- Kill cancer cells from within
- Engage the immune system to fight cancer
- Disrupt conditions which allow cancer to grow
Kill cancer cells from within
Engage the immune system to fight cancer
Disrupt conditions which allow cancer to grow
We’re purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we're creating new possibilities for people with cancer.
Explore Our PipelineThe Promise of Cell Therapy at Kite
Kite, a Gilead Company, is singularly focused on achieving cures with cell therapy. We’re the only global company solely dedicated to the research, development, manufacturing and commercialization of cell therapy, where we’re relentlessly focused on delivering hope to patients who need it most.
Learn More About KiteClinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We currently offer more than 25 therapies in the United States and are rapidly growing our portfolio through internal research and development and external collaborations.
Progress
We're transforming how cancer is treated by collaborating with partners from across the entire oncology community, including advocates, patients, industry and academia.
Partnerships play a key role in our growing pipeline and capabilities. Through approximately 40 active alliances and collaborations, we’re joining forces with some of the most promising oncology companies to access external sources of innovation, pursue next-generation cancer therapies and expand potential indications in our pipeline.
Latest News
Some of the content on this page is not intended for users outside the U.S.